PDF(Pubmed)
Abstract：
Background: FxCycleTM Violet (FCV) based flow cytometric (FCM) DNA ploidy analysis is a rapid and simple tool that can substantiate in characterizing the biological behaviour across the spectrum of haematological malignancies and correlates with cytogenetic studies. Materials and Methods: In this prospective study, we performed simultaneous immunophenotyping with FCV based on ploidy analysis in n=132 consecutive new samples, comprising n=110 samples of haemato-lymphoid neoplasms, including acute leukemias (n=67, 60.9%), CML with myeloid blast crisis (n=1, 0.9%), MDS with excess blasts (n=2, 1.8%), mature B cell/ T cell neoplasms (n=37, 33.7%), multiple myeloma (n=3, 2.7%) along with n=22 normal samples. The FCM DNA data was compared with corresponding conventional karyotyping results, wherever available. Results: In FCM ploidy analysis (n=110), the overall DNA index (DI) ranged from 0.81 to 2.17 and S-Phase fraction (SPF) from 0.1-31.6%. Diploidy was seen in n = 90 (81.8%), low-hyperdiploidy in n = 10 (9.1%), high-hyperdiploidy in n = 7 (6.4%) with one case each (0.9% each) having near-tetraploidy, high-hypodiploidy and low-hypodiploidy. The DI of all viable cell populations in normal samples ranged from 0.96-1.05. Conventional karyotyping was performed in n=76/110 cases (70%) with n= 11/76 (15%) culture failures. The modal chromosome number ranged from 45 to 63. A concordance of 95.4% (n=62/65) was noted with corresponding FCM DI. Conclusion: FCV-based ploidy is a sensitive technique that provides complementary information and ascertains a strong correlation with conventional cytogenetics across all haemato-lymphoid neoplasms. It can detect aneuploidy in all B-ALL and myeloma cases, even in hemodiluted samples with cytogenetic culture failure; supplement the diagnoses of erythroleukemia, and provide a useful screen for a higher grade lymph node disease in lymphoma cases with SPF > 3%.
摘要：
背景：基于FxCycleTM紫罗兰（FCV）的流式细胞术（FCM）DNA倍性分析是一种快速而简单的工具，可以证实整个血液恶性肿瘤的生物学行为特征，并与细胞遗传学研究相关。材料和方法：在这项前瞻性研究中，我们在n=132个连续的新样本中，基于倍性分析，用FCV进行了同时免疫表型分析，包括n=110个血液淋巴样肿瘤样本，包括急性白血病（n=67，60.9%），CML伴髓样急变（n=1，0.9%），有过量母细胞的MDS（n=2，1.8%），成熟B细胞/T细胞肿瘤（n=37，33.7%），多发性骨髓瘤（n=3，2.7％）以及n=22正常样本。将FCMDNA数据与相应的常规核型分析结果进行比较，无论哪里可用。结果：在FCM倍性分析中（n=110），总体DNA指数（DI）为0.81至2.17，S期分数（SPF）为0.1-31.6％。在n=90（81.8%）中观察到二倍体，n=10（9.1％）的低超二倍体，n=7（6.4％）的高超二倍体，每个病例（每个0.9％）具有近四倍体，高亚二倍体和低亚二倍体。正常样品中所有活细胞群的DI范围为0.96-1.05。在n=76/110例（70％）和n=11/76（15％）培养失败的情况下进行了常规核型分析。模态染色体数目为45～63。与相应的FCMDI的一致性为95.4%(n=62/65)。结论：基于FCV的倍性是一种敏感的技术，可提供补充信息，并确定所有血液淋巴样肿瘤与常规细胞遗传学的强相关性。它可以检测所有B-ALL和骨髓瘤病例的非整倍体，即使在血液稀释的样品与细胞遗传学培养失败;补充诊断的红白血病,并为SPF>3％的淋巴瘤病例中更高级别的淋巴结疾病提供有用的筛查。
